IL309486A - A pharmacy product containing tesquinimod and a method for evaluating the cleanliness of this product - Google Patents
A pharmacy product containing tesquinimod and a method for evaluating the cleanliness of this productInfo
- Publication number
- IL309486A IL309486A IL309486A IL30948623A IL309486A IL 309486 A IL309486 A IL 309486A IL 309486 A IL309486 A IL 309486A IL 30948623 A IL30948623 A IL 30948623A IL 309486 A IL309486 A IL 309486A
- Authority
- IL
- Israel
- Prior art keywords
- product
- tasquinimod
- assessing
- purity
- product containing
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- ONDYALNGTUAJDX-UHFFFAOYSA-N tasquinimod Chemical compound OC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 ONDYALNGTUAJDX-UHFFFAOYSA-N 0.000 title 1
- 229950001899 tasquinimod Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21183481 | 2021-07-02 | ||
| PCT/EP2022/068063 WO2023275248A1 (en) | 2021-07-02 | 2022-06-30 | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309486A true IL309486A (en) | 2024-02-01 |
Family
ID=76764937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309486A IL309486A (en) | 2021-07-02 | 2022-06-30 | A pharmacy product containing tesquinimod and a method for evaluating the cleanliness of this product |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240277693A1 (https=) |
| EP (1) | EP4363404A1 (https=) |
| JP (1) | JP2024524158A (https=) |
| KR (1) | KR20240029029A (https=) |
| CN (1) | CN117500790A (https=) |
| AU (1) | AU2022303084A1 (https=) |
| CA (1) | CA3221689A1 (https=) |
| IL (1) | IL309486A (https=) |
| MX (1) | MX2023014668A (https=) |
| WO (1) | WO2023275248A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024306742A1 (en) * | 2023-06-28 | 2025-12-04 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of mpn |
| WO2025228998A1 (en) * | 2024-04-30 | 2025-11-06 | Institut National de la Santé et de la Recherche Médicale | Use of hdac4 inhibitors for the treatment of melanoma |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SG186430A1 (en) | 2010-07-09 | 2013-01-30 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| CN105367492B (zh) * | 2014-08-28 | 2018-07-03 | 杭州普晒医药科技有限公司 | 他喹莫德的晶型及其制备方法、其药物组合物和用途 |
| JP6647287B2 (ja) | 2014-09-23 | 2020-02-14 | アクティブ バイオテック エイビー | 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド |
| MX379401B (es) | 2014-11-19 | 2025-03-11 | Active Biotech Ab | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| BR112023000892A2 (pt) | 2020-07-23 | 2023-02-07 | Univ Erasmus Med Ct Rotterdam | Inibidor de uma proteína s100 para uso na prevenção ou tratamento de uma neoplasia mieloproliferativa, agente e método para identificar um indivíduo que sofre de uma neoplasia mieloproliferativa, e, métodos para identificar um indivíduo em risco de desenvolver mielofibrose e que se beneficie de um tratamento com um inibidor |
-
2022
- 2022-06-30 AU AU2022303084A patent/AU2022303084A1/en active Pending
- 2022-06-30 CN CN202280043401.8A patent/CN117500790A/zh active Pending
- 2022-06-30 JP JP2023578067A patent/JP2024524158A/ja active Pending
- 2022-06-30 US US18/571,472 patent/US20240277693A1/en active Pending
- 2022-06-30 EP EP22741222.8A patent/EP4363404A1/en active Pending
- 2022-06-30 MX MX2023014668A patent/MX2023014668A/es unknown
- 2022-06-30 KR KR1020247002056A patent/KR20240029029A/ko active Pending
- 2022-06-30 CA CA3221689A patent/CA3221689A1/en active Pending
- 2022-06-30 IL IL309486A patent/IL309486A/en unknown
- 2022-06-30 WO PCT/EP2022/068063 patent/WO2023275248A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023014668A (es) | 2024-01-12 |
| EP4363404A1 (en) | 2024-05-08 |
| KR20240029029A (ko) | 2024-03-05 |
| WO2023275248A1 (en) | 2023-01-05 |
| AU2022303084A1 (en) | 2024-01-25 |
| US20240277693A1 (en) | 2024-08-22 |
| CA3221689A1 (en) | 2023-01-05 |
| CN117500790A (zh) | 2024-02-02 |
| JP2024524158A (ja) | 2024-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL309486A (en) | A pharmacy product containing tesquinimod and a method for evaluating the cleanliness of this product | |
| IL284782A (en) | A continuous manufacturing process for biologics manufacturing by integration of drug substance and drug product processes | |
| GB201900985D0 (en) | A packing case and method of manufacture thereof | |
| NO20210436A1 (en) | Product handling system | |
| HK40108370A (en) | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product | |
| ZA202110948B (en) | Pharmaceutical dosage forms and methods for their production | |
| PL3530340T3 (pl) | Sposób i instalacja do oddzielania kwaśnych składników gazowych z gazu syntezowego zawierającego karbonylki metali | |
| IL280415A (en) | A ready-to-sell packaging unit containing at least one medical product, a system containing several packaging units and a method for creating such a packaging unit | |
| GB202100819D0 (en) | Process and Product Thereof | |
| GB2588207B (en) | A container and method and apparatus for adding a product to a container | |
| IL297715A (en) | pharmaceutical process | |
| CA233192S (en) | Capsule for pharmaceutical products | |
| ZA202000827B (en) | Packaged retail insurance product and process and system for implementation thereof | |
| EP4038383A4 (en) | APPARATUS AND METHOD FOR MONITORING AND RECORDING DISINTEGRATION TIMES FOR PHARMACEUTICAL PRODUCTS | |
| GB201815798D0 (en) | System and method for a pharmaceutical product | |
| PL3969390T3 (pl) | Opakowanie na produkt żywnościowy i sposób wytwarzania opakowania na produkt żywnościowy | |
| GB202304474D0 (en) | Dementia alteration medicine | |
| GB202009633D0 (en) | System and method for the discharge of product from a container | |
| EP3638433B8 (en) | A fastening apparatus comprising a die cartridge and a die changer and method of fastening at least two sheets of material | |
| GB202101079D0 (en) | Pharmaceutical products | |
| EM87404270003S (fr) | Capsules pour produits pharmaceutiques (partie de -) | |
| EM87404270002S (da) | Kapsler til farmaceutiske produkter (del af -) | |
| EM87404270001S (cs) | Kapsle na farmaceutické výrobky, blistry (část -) | |
| GB201918128D0 (en) | 3-oxindoles and a method of synthesis thereof | |
| EM79849920003S (bg) | Капсули за фармацевтични продукти |